SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.70-0.8%Jan 23 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: opalapril who wrote (9095)3/10/1999 11:37:00 PM
From: aknahow  Read Replies (2) of 17367
 
I would have to call again and I am not really sure of what he said or if I want to directly repeat it. Still sorting it out here, and if Bluegreen explains the 125 remark, I will post more right here and you will understand what he said.

This is one of the values of subscribing. Even if one never knows if one can believe what he says, it is always interesting. He was very bullish on CORR and provided details I had not head elsewhere. Strange but when I have not heard it before, I assume it's correct. With XOMA and the people hours put in here and at Yahoo I wonder if he knows as much. But because he is important to any company I have to believe he can get better access and information.

He said original trial was based on 125, and in essence that if they have not got to the "number" derived from original thoughts of how many would die out of 125 when there are 370 accrued Neuprex is working. No deaths in Neuprex arm, is implied thought.

He said the DSMB told XOMA to start talking to the FDA. I believe he said XOMA said this in their press release. (I DON'T THINK SO)

Mentioned they are accruing about 8 per week and the close bit. Said 6 then refined it to 4 weeks.

Did not say much more.

O.K. now tell me what opalapril means!!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext